In Reply: Dr Siffroi and colleagues describe and advocate the current policies in France.1 They indicate that following systematic guidelines for screening and risk stratification of both donors and recipients is standard practice in France, but such a strategy has not been embraced in the United States. However, we do not believe that the French approach would be particularly effective for the identification of HCM, a relatively common monogenic disorder (and the most common cause of sudden death in the young), occurring in 1:500 of the general population.2 Karyotype analysis, symptom onset, and history-taking (as practiced in France) would be unreliable disease markers for HCM and for many other potentially transmittable genetic diseases.
Maron BJ, Rehm HL. Heritable Disease and Sperm Donation—Reply. JAMA. 2010;303(7):617-619. doi:10.1001/jama.2010.124